An anion and small molecule inhibition study of the β-carbonic anhydrase from Staphylococcus aureus

Linda J. Urbanski, Daniela Vullo, Seppo Parkkila, and Claudiu T. Supuran

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Neurofarba Department, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Firenze, Italy; Neurofarba Department, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Firenze, Italy

ABSTRACT
Pathogenic bacteria resistant to most antibiotics, including the methicillin-resistant Staphylococcus aureus (MRSA) represent a serious medical problem. The search for new antinfectives, possessing a diverse mechanism of action compared to the clinically used antibiotics, has become an attractive research field. S. aureus DNA encodes a β-class carbonic anhydrase, SauBCA. It is a druggable target that can be inhibited by certain aromatic and heterocyclic sulphamides. Here we investigated inorganic anions and some other small molecules for their inhibition of SauBCA. The halides, nitrite, nitrate, bicitonaric acid, bisulfite, sulphate, stannate, and N,N-diethylthiocarbaminate were submillimolar SauBCA inhibitors with K_i's in the range of 0.26 – 0.91 mM. The most effective inhibitors were sulfamate, sulfoxate, phenylboronic acid, and phenylarsenic acid with K_i's of 7 – 43 μM. Several interesting inhibitors detected here may be considered lead compounds for the development of even more effective derivatives, which should be investigated for their bacteriostatic effects.

ARTICLE HISTORY
Received 22 April 2021
Revised 11 May 2021
Accepted 14 May 2021

KEYWORDS
β-carbonic anhydrase; Staphylococcus aureus; kinetics; inhibition; anions

1. Introduction
Staphylococcus aureus is a Gram-positive bacterium that infects nearly all host tissues in many mammalian species, including humans and livestock, causing severe morbidity and mortality. It belongs to the sadly famous ESKAPE group of bacterial pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) that are resistant to many clinically used antibiotics including methicillin and vancomycin. As a consequence, the treatment of such infection remains particularly challenging if not impossible in severe cases. Thus, there is an urgent need for new classes of antibiotics which can either inhibit the growth of these pathogens and subsequently kill them, or of compounds which can restore the sensitivity of resistant bacteria to the various classes of clinically used agents. The inhibitors of the widespread metalloenzyme, carbonic anhydrase (CA, EC 4.2.1.1), were recently shown to be effective in inhibiting the growth (possessing a significant bactericidal activity) of some drug-resistant pathogens, such as vancomycin-resistant Enterococci and Neisseria gonorrhoeae.

In fact, CAs are present in most microorganisms including bacteria and are encoded by at least four genetic families (although new ones may still exist to be reported), which are the α-, β-, γ-, and i-CAs. In some bacteria, such as Escherichia coli, the CAs are essential for the survival of the organism. For others, such as Helicobacter pylori, the CAs assure the acclimation of the bacterium in the specific niches (gastric and duodenal mucosa) in which it thrives, whereas for others, such as Vibrio cholerae, these enzymes participate in the secretion of bicarbonate which is a virulence factor of this pathogen. In the last decade, many representatives of these enzymes, belonging to all four classes present in bacteria, were cloned and characterised both biochemically and structurally in the search for inhibitors. This can eventually lead to the development of new antibacterial agents. Among the various species which have been characterised in this way are E. coli, H. pylori, Mycobacterium tuberculosis, Vibrio cholerae, Pseudomonas aeruginosa, Porphyromonas gingivalis, Streptococcus spp., Staphylococcus aureus, etc. Although the scientific community was rather sceptical for a long time that bacterial CA inhibition may lead to significant growth inhibition of pathogenic bacteria, Flaherty’s group recently published the long-awaited proof-of-concept that inhibition of bacterial CAs may lead to antibiotics with novel mechanisms of action. They showed that the sulphonamide CA inhibitor (CAI) acetazolamide and some of its derivatives, as well as dorzolamide, outperformed the current drug of choice, linezolid, both in vitro and in vivo, for inhibiting the growth of vancomycin-resistant enterococci (VRE) and N. gonorrhoeae. Furthermore, other groups have demonstrated that CAs may exhibit reduced potential for the development of drug resistance, as in the case of H. pylori and ethoxzolamide as CAI. Mutations were observed in several bacterial genes, including the bacterial α-CA gene, but the pathogen remained susceptible to the drug at clinically relevant concentrations.

Recently, we cloned and characterised a β-CA of S. aureus (SauBCA), an enzyme that possesses a high catalytic activity for the physiologic CO2 hydration reaction to bicarbonate and protons, with the following kinetic parameters: k_cat of 1.46 x 10^{5} s^{-1} and a k_cat/K_M of 2.56 x 10^{-4} s^{-1} M^{-1}. This enzymatic function was
inhibited by various sulphonamide derivatives, which represent one of the main classes of inhibitors of these enzymes. In this study, we continue the exploration of the inhibitors of SauBCA, reporting its inhibition profile with anions and other small molecules known to inhibit CAs.

2. Materials and methods

2.1. Chemistry

Anions and small molecules were commercially available reagents of the highest available purity from Sigma-Aldrich (Milan, Italy). Purity of tested compounds was higher than 99%.

2.2. Enzymology

SauBCA was a recombinant enzyme obtained in-house as described earlier.

2.3. CA activity and inhibition measurements

An Applied Photophysics stopped-flow instrument was used for assaying the CA catalysed CO₂ hydration activity. Phenol red at a concentration of 0.2 mM was used as a pH indicator (working at the absorbance maximum of 557 nm) with 10 mM Hepes (pH 7.4) as a buffer, and in the presence of 10 mM NaClO₄ for maintaining constant ionic strength. The initial rates of the CA-catalysed CO₂ hydration reaction were followed for a period of 10 – 100 s. The CO₂ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5 – 10% of the reaction were used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitors (10 – 20 mM) were prepared in distilled-deionized water and dilutions up to 0.01 μM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay in order to allow for the formation of the enzyme-inhibitor complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng–Prusoff equation, whereas the kinetic parameters for the uninhibited enzymes were obtained from Lineweaver-Burk plots, as reported earlier. The results represent the mean from at least three different determinations (data not shown). The SauBCA concentration in the assay system was 9.7 nM.

3. Results and discussion

Inorganic anions represent a well-characterised class of CAIs. Our study included anions known to have a high affinity in solution for complexing metals, such as halides and especially pseudohalides (cyanide, cyanate, thiocyanate, azide, etc.), as well as those which do not easily form complexes with transition metal ions (e.g. sulphate, selenate, tellurate, tetraborate, etc.). Both groups of anions have been shown to possess inhibitory action against all classes of CAs investigated so far, from prokaryotes to eukaryotes. Furthermore, small molecules such as sulfamide, sulfamic acid, phenylboronic, and phenylarsenic acid also possess such properties. In this study, we investigated a panel of such anions and small molecules for the inhibition of SauBCA (Table 1). The inhibition data of the abundant human (h) isoforms hCA I and II as well as those of another bacterial CA, NgCA from N. gonorrhoeae are also shown in Table 1 for comparison.

### Table 1. Inhibition constants (Kᵢ) of anion inhibitors against hCA I, II and the bacterial enzymes NgCA and SauBCA, measured by a stopped-flow CO₂ hydration assay

| Anionb | hCA I (mM) | hCA II (mM) | NgCA (mM) | SauBCA (mM) |
|--------|------------|-------------|-----------|-------------|
| F⁻     | >300       | >300        | 8.3       | 0.48        |
| Cl⁻    | 6          | 200         | 4.8       | 0.69        |
| Br⁻    | 4          | 63          | 4.0       | 0.26        |
| I⁻     | 0.3        | 26          | 9.6       | 0.72        |
| CN⁻    | 0.0007     | 0.03        | 0.43      | 3.7         |
| SCN⁻   | 0.2        | 1.6         | 0.92      | 28.6        |
| CN²⁻   | 0.0005     | 0.02        | 1.0       | 4.1         |
| NO₃⁻   | 0.0012     | 1.5         | 2.1       | 7.4         |
| NO₂⁻   | 8.4        | 63          | 0.59      | 0.56        |
| NO₂⁻   | 7          | 35          | 0.85      | 0.41        |
| HCO₃⁻  | 12         | 85          | 1.3       | 0.42        |
| CO₂⁻   | 15         | 73          | 2.9       | 0.76        |
| HSO₄⁻  | 63         | >200        | 0.83      | 0.91        |
| HS⁻    | 0.0006     | 0.04        | 0.55      | 19.3        |
| NH₄SO₄| 0.31       | 1.13        | 0.058     | 0.009       |
| NH₄SO₃| 0.021      | 0.39        | 0.024     | 0.043       |
| PhAsO₄| 31.7       | 49          | 0.74      | 0.007       |
| PhB(OH)₂| 58.6      | 23          | 0.15      | 0.008       |
| ClO₃⁻  | >200       | >200        | >100      | >100        |
| SnO₂⁻  | 0.57       | 0.83        | 1.7       | 0.32        |
| SeO₂⁻  | 118        | 112         | 0.87      | 4.8         |
| TeO₂⁻  | 0.66       | 0.92        | 0.76      | 42.0        |
| OsO₂⁻  | 0.92       | 0.95        | 2.3       | 6.0         |
| PoO₂⁻  | 25.8       | 48          | 4.9       | >100        |
| V₂O₅⁻ | 0.54       | 0.57        | 2.8       | >100        |
| B₂O₅⁻ | 0.64       | 0.95        | 0.65      | 8.7         |
| ReO₄⁻  | 0.31       | 0.75        | 0.96      | >100        |
| RuO₄⁻  | 0.101      | 0.69        | 1.9       | >100        |
| S₂O₅²⁻| 0.107      | 0.084       | 0.79      | >100        |
| SeCN⁻  | 0.085      | 0.086       | 0.66      | 5.5         |
| NH₄(SO₃)₂⁻| 0.31 | 0.76 | 0.25 | >100 | |
| FSO₃⁻ | 0.79       | 0.46        | 0.61      | 8.9         |
| CF₃⁻  | 0.0087     | 0.0888      | 0.088     | 11.4        |
| EMNCS⁻ | 0.00079    | 0.0031      | 0.0051    | 0.64        |
| PF₆⁻  | >100       | >100        | >100      | >100        |
| CF₃SO₄⁻| >100       | >100        | >100      | >100        |

*From mean from three different assays, measured by a stopped-flow technique (errors were in the range of ± 5 – 10% of the reported values); **As sodium salts, except sulphamide and phenylboronic acid.

The following observations can be delineated from the data presented in Table 1 regarding the inhibition of SauBCA with anions and small molecules:

i. anions with a rather low propensity for complexating metal ions, such as perchlorate and hexafluorophosphate, and triflate, did not inhibit SauBCA significantly with concentrations up to 100 mM in the assay system. This is also the case for their interaction with hCA I and II, as well as many other CAs belonging to all known classes. For this reason, we used perchlorate at 10 mM concentration for maintaining constant ionic strength in the stopped-flow assays, as mentioned in Materials and methods. Other anions, such as pyrophosphate, divanadate, perruthenate, perhenenate, peroxydisulfate and imidisulfonate, were also in this category of non-inhibiting anions. It should be noted, however, that some of them act as rather efficient anion inhibitors of other enzymes than SauBCA, as shown in Table 1.

ii. The following anions showed weak inhibitory action against SauBCA: thiocyanate, hydrogensulfide, tellurate, and trithiocarbonate, with inhibition constants in the range of 11.4 – 42 mM (Table 1). Except for tellurate, which is not a high-affinity ligand for metal ions, the other three anions mentioned here are either very good coordinating agents for...
transition metal ions (thiocyanate, hydrogensulfide, and thiocarbonate) or quite effective CAIs (see the thiocarbonate data for hCA I, II and NgCA in Table 1). Additionally, in some cases, the X-ray crystal structure of their complexes with hCA II is also available\(^{26,27}\). Thus, these low inhibition constants against SauBCA deserve a better investigation in order to understand the structural features of this enzyme active site, which for the moment has not been crystallised.

iii. Effective, millimolar inhibition was observed for the following anions: cyanate, cyanide, azide, selenate, perosmate, tetraborate, selenocyanate, and fluorosulfonate, with \( K_s \) in the range of 3.7–8.9 mM. It should be noted that some of these anions (e.g. cyanide, cyanate) are extremely potent, micromolar hCA I inhibitors, whereas their activity against hCA II and NgCA are usually in the millimolar or submillimolar range.

iv. The halides, nitrite, nitrate, bicarbonate, carbonate, bisulphite, sulphate, stannate, and \( N,N\)-diethyldithiocarbamate were even more effective as SauBCA inhibitors with \( K_s \) in the range of 0.26–0.91 mM (Table 1). Among the halides, bromide was the most effective inhibitor, whereas the isosteric/iso electronic nitrate and bicarbonate had very similar inhibitory behaviour. Sulphate, which is an extremely weak hCA I and II inhibitor, is on the other hand much more effective as an inhibitor of bacterial CAs. In fact, many such bacterial enzymes have been purified in the presence of extremely high concentrations of sulphate and showed no catalytic activity due to inhibition by the anion present in the buffer or the assay system\(^{14}\).

v. The most effective inhibitors detected in the current study were sulfamide, sulfamate, phenylboronic acid, and phenylarsonic acid, which showed \( K_s \) in the range of 7–43 \( \mu \)M. In fact, these compounds are known to inhibit many CAs of different classes, and X-ray crystal structures have even been reported for some of the enzyme-inhibitor complexes\(^{12,28}\).

4. Conclusions

SauBCA is a high activity \( \beta \)-CA present in the genome of the bacterial pathogen \( S. aureus \), known for its extensive drug resistance to classical antibiotics. We investigated here its inhibition with a series of inorganic and organic anions. Perchlorate, hexafluorophosphate, triflate, pyridophosphate, divanadate, perrenenate, peroxysulfate, and inimidisulfonate did not show any significant inhibitory action against this enzyme with concentrations up to 100 mM in the assay system. Thiocyanate, hydrogensulfide, telluride, and trithiocarbonate were weak inhibitors with \( K_s \) in the range of 11.4 – 42 mM, whereas cyanate, cyanide, azide, selenate, perosmate, tetraborate, selenocyanate, and fluorosulfonate showed \( K_s \) in the range of 3.7 – 8.9 mM. The halides, nitrite, nitrate, bicarbonate, carbonate, bisulphite, sulphate, stannate, and \( N,N\)-diethyldithiocarbamate were more effective as SauBCA inhibitors with \( K_s \) in the range of 0.26 – 0.91 mM, but the most effective inhibitors were sulfamide, sulfamate, phenylboronic acid, and phenylarsonic acid, which showed \( K_s \) in the range of 7 – 43 \( \mu \)M. Several inhibitors detected here may be considered as lead compounds for the development of even more effective derivatives, which should thereafter be investigated for their bacteriostatic effects.

Acknowledgements

CTS thanks the Italian Ministry for University and Research (MIUR), project FISR2019_04819 BacCAD. SP is thankful for the funding from the Academy of Finland and Jane & Aatos Erkko Foundation.

Disclosure statement

The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Funding

The research program was also funded by the Academy of Finland, and Jane & Aatos Erkko Foundation and Italian Ministry for University and Research (MIUR) [FISR2019_04819 BacCAD].

ORCID

Seppo Parkkila http://orcid.org/0000-0001-7323-8536
Claudiu T. Supuran http://orcid.org/0000-0003-4262-0323

References

1. (a) Ford CA, Hurford IM, Cassat JE. Antivirulence strategies for the treatment of \( Staphylococcus aureus \) infections: a mini review. Front Microbiol 2020;11:632706. (b) Cheung GYC, Bae JS, Liu R, et al. Bacterial virulence plays a crucial role in MRSA sepsis. PLoS Pathog 2021;17:e1009369.

2. (a) Mahros MA, Abd-Elghany SM, Sallam KI. Multidrug-, methicillin-, and vancomycin-resistant \( Staphylococcus aureus \) isolated from ready-to-eat meat sandwiches: an ongoing food and public health concern. Int J Food Microbiol 2021;346:109165. (b) Cortes MF, Botelho AMN, Bandeira PT, et al. Reductive evolution of virulence repertoire to drive the divergence between community- and hospital-associated methicillin-resistant \( Staphylococcus aureus \) of the ST1 lineage. Virulence 2021;12:951–67.

3. (a) Chojnacki M, Cao X, Flaherty DP, Dunnam PM. Optimization of 2-acylamino-cycloalkylthiophene derivatives for activity against \( Staphylococcus aureus \) RnpA. Antibiotics 2021;10:369. (b) Piras C, Di Cicco PA, Soggiu A, et al. \( S. aureus \) biofilm protein expression linked to antimicrobial resistance: a proteomic study. Animals 2021;11:966. (c) Princiotto S, Mazzini S, Musso L, et al. New antimicrobials based on the adarotene scaffold with activity against multi-drug resistant \( Staphylococcus aureus \) and vancomycin-resistant \( Enterococcus \). Antibiotics 2021;10:126.

4. (a) Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat 2020;30:963–82. (b) Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34. (c) Campestre C, De Luca V, Carradori S, et al. Carbonic anhydrases: new perspectives on protein functional role and inhibition in \( Helicobacter pylori \). Front Microbiol 2021;12:629163.

5. (a) Kaur J, Cao X, Abutaleb NS, et al. Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant \( Enterococcus \). J Med Chem 2020;63:9540–62. (b)
Abutaleb NS, Elkashif A, Flaherty DP,Seleem MN. In vivo antibacterial activity of acetazolamide. Antimicrob Agents Chemother 2021;65:e01715–20. (c) Abutaleb NS, Elhassany AEM, Flaherty DP,Seleem MN. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ 2021;9:e11059.

6. Hewitt CS, Abutaleb NS, Elhassany AEM, et al. Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis 2021;(in press).

7. (a) Smith KS, Jakubzick C,Whittam TS,Ferry JG. Carbonic anhydrase is an ancient enzyme widespread in prokaryotes. Proc Natl Acad Sci USA 1999;96:15184–9. (b) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;30:325–32. (c) Abuaita BH, Withey JH. Bicarbonate induces Vibrio cholerae virulence gene expression by enhancing ToxT activity. Infect Immun 2009;77:4111–20.

8. (a) Merlin C, Masters M,McAteer S, Coulson A. Why is carbonic anhydrase essential to Escherichia coli? J Bacteriol 2003;185:6415–24. (b) Vullo D,Kumar RSS, Scozzafava A, et al. Sulphonamide inhibition studies of the β-carbonic anhydrase from the bacterial pathogen Clostridium perfringens. J Enzyme Inhib Med Chem 2018;33:31–6. (c) Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat 2018;28:745–54. (d) Del Prete S, Nocentini A, Supuran CT,Capasso C. Bacterial i-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territiori. J Enzyme Inhib Med Chem 2020;35:1060–8.

9. (a) Rahman MM, Tikhomirova A,Modak JK, et al. Antibacterial activity of ethoxzolamide against Helicobacter pylori strains S51 and 26695. Gut Pathog 2020;12:20. (b) Modak JK, Tikhomirova A,Gorrell RJ, et al. Anti-Helicobacter pylori activity of ethoxzolamide. J Enzyme Inhib Med Chem 2019;34:1660–7. (c) Modak JK, Liu YC, Supuran CT, Roujeinikova A. Structure-activity relationship for sulfonamide inhibition of Helicobacter pylori α-carbonic anhydrase. J Med Chem 2016;59:11098–109.

10. (a) Aspatwar A, Kairys V, Rala S, et al. Mycobacterium tuberculosis β-carbonic anhydrases: novel targets for developing antituberculosis drugs. Int J Mol Sci 2019;20:5153. (b) Wani TV,Bua S, Khude PS, et al. Evaluation of sulphonamide derivatives acting as inhibitors of human carbonic anhydrase isoforms I, II and Mycobacterium tuberculosis β-class enzyme Rv3273. J Enzyme Inhib Med Chem 2018;33:962–71. (c) Aspatwar A, Hammaren M, Koskinen S, et al. β-CA-like inhibitor dithiocarbamate Fc14-584B: a novel antitumourbacteri al agent with potential to treat drug-resistant tuberculosis. J Enzyme Inhib Med Chem 2017;32:832–40. (d) Carta F, Maresca A,Covarrubias AS, et al. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009;19:6649–54. (e) Nishimori I,Minakuchi T,Vullo D, et al. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem 2009;52:3116–20.

11. (a) Del Prete S,Bua S, Supuran CT, Capasso C. Escherichia coli γ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enzyme Inhib Med Chem 2020;35:1545–54. (b) Nocentini A, Del Prete S,Mastrolorenzo MD, et al. Activation studies of the β-carbonic anhydrases from Escherichia coli with amino acids and amines. J Enzyme Inhib Med Chem 2020;35:1379–86. (c) Del Prete S,De Luca V, Bua S, et al. The effect of substituted benzene-sulphonamides and clinically licensed drugs on the catalytic activity of CynT2, a carbonic anhydrase crucial for Escherichia coli life cycle. Int J Mol Sci 2020;21:4175.
16. (a) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86. (b) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81. (c) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.

17. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.

18. (a) Angeli A, Pinteala M, Maier SS, et al. Inhibition of $\alpha$, $\beta$, $\gamma$, $\delta$, $\zeta$, and $\eta$-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine. J Enzyme Inhib Med Chem 2019;34:644–50. (b) Urbański LJ, Di Fiore A, Azizi L, et al. Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from *Trichomonas vaginalis*. J Enzyme Inhib Med Chem 2020;35:1292–9.

19. (a) Petreni A, De Luca V, Scaloni A, et al. Anion inhibition studies of the Zn(II)-bound $\gamma$-carbonic anhydrase from the Gram-negative bacterium *Burkholderia territorii*. J Enzyme Inhib Med Chem 2021;36:372–6. (b) De Luca V, Petreni A, Nocentini A, et al. Effect of sulfonamides and their structurally related derivatives on the activity of $\gamma$-carbonic anhydrase from *Burkholderia territorii*. Int J Mol Sci 2021;22:571.

20. (a) Bonardi A, Nocentini A, Bua S, et al. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isof orm matching and selectivity of action. J Med Chem 2020;63:7422–44. (b) Bouzina A, Berredjem M, Nocentini A, et al. Nihydrins inhibit carbonic anhydrases directly binding to the metal ion. Eur J Med Chem 2021;209:112875.

21. (a) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29. (b) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enz Inhib Med Chem 2016;31:689–94. (c) Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80. (d) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72. (e) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.

22. (a) Urbański LJ, Angeli A, Hytönen VP, et al. Inhibition of the newly discovered $\beta$-carbonic anhydrase from the protozoan pathogen *Trichomonas vaginalis* with inorganic anions and small molecules. J Inorg Biochem 2020;213:111274. (b) Haapanen S, Bua S, Kuuslahti M, et al. Cloning, characterization and anion inhibition studies of a $\beta$-carbonic anhydrase from the pathogenic protozoan *Entamoeba histolytica*. Molecules 2018;23:3112. (c) Vullo D, Lehneck R, Donald WA, et al. Anion inhibition studies of the $\beta$-class carbonic anhydrase CAS5 from the filamentous ascomycete *Sordaria macrospora*. Metabolites 2020;10:93.

23. (a) Vullo D, Syrjänen L, Kuuslahti M, et al. Anion inhibition studies of a beta carbonic anhydrase from the malaria mosquito *Anopheles gambiæ*. J Enzyme Inhib Med Chem 2018;33:359–63. (b) Perfetto R, Del Prete S, Vullo D, et al. Sequence analysis, kinetic constants, and anion inhibition profile of the nacrein-like protein (CgilNAP2X1) from the pacific oyster *Magallana gigas* (ex- *Crassostrea gigas*). Mar Drugs 2017;15:270. (c) Del Prete S, Vullo D, Di Fonzo P, et al. Anion inhibition profiles of the $\gamma$-carbonic anhydrase from the pathogenic bacterium *Burkholderia pseudomallei* responsible of melioidosis and highly drug resistant to common antibiotics. Bioorg Med Chem 2017;25:575–80.

24. (a) Supuran CT. Bortezomib inhibits bacterial and fungal $\beta$-carbonic anhydrases. Bioorg Med Chem 2016;24:4406–9. (b) Supuran CT. Bortezomib inhibits mammalian carbonic anhydrases. Bioorg Med Chem 2017;25:5064–7.

25. Nocentini A, Hewitt CS, Mastrololendo MD, et al. Anion inhibition studies of the $\alpha$-carbonic anhydrases from *Neisseria gonorrhoeae*. J Enzyme Inhib Med Chem submitted.

26. (a) Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct – an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010;20:474–8. (b) Innocenti C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbonate. Bioorg Med Chem Lett 2010;20:1548–50.

27. Huang S, Xue Y, Sauer-Eriksson E, et al. Crystal structure of carbonic anhydrase from *Neisseria gonorrhoeae* and its complex with the inhibitor acetazolamide. J Mol Biol 1998;283:301–10.

28. Abbate F, Supuran CT, Scozzafava A, et al. Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J Med Chem 2002;45:3583–7.